Automated external defibrillators (AEDs) are compact, portable electronics that shock the heart through the chest. Defibrillation is used by AEDs to diagnose cardiac arrhythmias and ventricular tachycardias and return the heart rate to normal. AEDs are essential in the management of SCA, which is caused by ventricular tachycardia and fibrillation. SCA, which accounts for more than 350,000 medical emergencies annually in the United States alone, is a primary cause of death worldwide, according to the American Heart Association (AHA).
The market for automated external defibrillator in 2021 was worth USD 1.71 billion, and by 2030, it will be worth USD 3.68 billion, expanding at an 8.77% CAGR during the forecast period.
The need for automated external defibrillators is driven by factors including expanding government activities regarding public access defibrillator (PAD) programs, which will result in the establishment of defibrillators in crowded public spaces. The market for automated external defibrillators will continue to increase due to the rising prevalence of cardiac illnesses, an aging population, and technological developments in defibrillator technology.
Market Dynamics
Drivers
The market for automated external defibrillators is developing due to the rising incidence of lifestyle-related disorders such as diabetes, hypertension, obesity, and dyslipidemia.
Additionally, the market is driven by growing technological developments in automated external defibrillator devices. A fast-expanding geriatric population at elevated risk of specific illnesses, and a rise in the prevalence of cardiac ailments. Globally increasing rates of cardiovascular disorders, including coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other illnesses, are some of the major drivers propelling the market.
Restraints
Hardware, software, and battery issues may lead to delayed treatment, hindering market expansion.
Opportunity
Market players are consistently raising their investments in the industry due to the progress of innovation and technology and the rising demand for automated external defibrillators, which will fuel market expansion during the forecast period. Definitive agreements for MicroPort Cardiac Rhythm Management Limited’s USD 150 million Series C financing were signed in July 2021. This subsidiary of MicroPort Scientific Corporation specializes in manufacturing and commercializing implantable pacemakers and defibrillator equipment and technologies to manage cardiac rhythm disorders. An increase in market participant investment of this magnitude is influencing market growth.
Market Segmentation
By Type
On the basis of type, the automated external defibrillators market is segmented into fully automated defibrillators and semi-automated defibrillators.
Expanding the number of strong approaches by states, administrative bodies, and medical care associations is expected to fuel the market over the estimated period. For instance, the IRC (Italian Revival Gathering) revealed that the proposed regulation on AEDs in Italy was supported by the Parties Commission of the Chamber in July 2021. The law accommodates around 10 million EUR (about USD 11.36 million) for the execution of free AEDs throughout the following five years, among different arrangements.
In Australia, the public authority organization SA Rescue Vehicle Administration (SAAS), suggests utilization of a defibrillator as soon as conceivable to expand the individual’s possibilities of endurance. Both self-loader and programmed AEDs are suggested while manual defibrillators are suggested for use via prepared experts as it were. AEDs are likewise suggested over a manual defibrillator in low-keenness settings, including clinical facilities and unified well-being and dental centers, because of their usability.
The semi-automated external defibrillators segment ruled the entire market and will expand at a CAGR of 9.32% over the forecast period.
By End-User
On the basis of end-user, the market is segmented into specialized cardiovascular disease treatment centers, hospitals & clinics, and ambulatory surgery centers.
The Hospitals ruled the entire market with significant revenue share because of the high demand for implanting ICDs in hospitals. Defibrillator installation will improve market growth prospects.
Regional Analysis
North America is the leading regional market and will expand at a 9.3% CAGR. The US is the primary driver of regional expansion. The regional market is expanding due to the frequency of cardiovascular disorders, the introduction of new products, and the presence of major market participants in the US.
By 2030, Europe will expand rapidly at a 9.70% CAGR generating USD 603 million in revenue. The expanding European AED market will receive the majority of its support from Germany and France. The high prevalence of cardiovascular disorders in Germany is the key factor driving the market for automated external defibrillators, together with the introduction of new devices and the country’s extensive infrastructure for research and development. (AEDs).
Key Players
- Stryker Corporation
- Koninklijke Philips NV
- Asahi Kasei Corporation (ZOLL Medical Corporation)
- ViVest Medical
- Shenzhen Mindray Bio-Medical Electronics Co. Ltd
- Nihon Kohden Corporation
- Mediana Co. Ltd
- Schiller AG
- CU Medical System Inc.
- BPL Medical Technologies Pvt. Ltd
The market for automated external defibrillators in 2021 was worth USD 1.71 billion, and by 2030 it will be worth USD 3.68 billion. Expanding at an 8.77% CAGR during the forecast period. The growing prevalence of cardiac illnesses, the growing elderly population, and technological breakthroughs in the area. And increased market participant investment all contribute to the growth of the automated external defibrillator market globally.
Nihon Kohden for example, detailed twofold digit development in worldwide deals in 2020 (counting the U.S. also, Latin America) because of the expanded interest during the Coronavirus pandemic. Deals in Mexico and Colombia, specifically, recorded 200% development because of floods popular for Nihon Kohden’s patient screens, defibrillators, and ventilators.
In June 2020, Philips got FDA freedom for HeartStartFRx and HeartStart FR3 mechanized outside defibrillators. HeartStart FR3 incorporates inventive elements to assist the clinical workforce and specialists on call with treating heart failure. While HeartStartFRx is a community mechanized outer defibrillator that highlights natural. Bit-by-bit voice directions, containing cardiopulmonary revival direction. For crisis use in school, work environments, and other public spaces, notwithstanding clinical expert use.
Mechanical progressions have prompted present-day outside defibrillators to turn out to be increasingly conservative and simpler to use. With the diminished need for support and inflated cost adequacy. AEDs in the U.S., for example, are valued between USD 900 and 2,000.
Related Reports:
Neuromodulation Devices Market Report – The global neuromodulation devices market will witness a robust CAGR of 10.28%, valued at $6.09 billion in 2021. Expected to appreciate and reach $14.17 billion by 2030, confirms Strategic Market Research. North America had the largest share globally, with a value of over 60% in 2021.
